XML 30 R19.htm IDEA: XBRL DOCUMENT

Non-Marketable Investments	12 Months Ended
Dec. 31, 2024
Investments, Debt and Equity Securities [Abstract]
Non-Marketable Investments	Note 9 – Non-Marketable Investments At December 31, 2024 and 2023, the carrying value of the Company’s non-marketable investments, which were composed of interests in technology-related private equity funds and an interest in a standalone real-time feedback company (see Note 2 - Divestiture), was $3.2 million and $1.2 million, respectively, and are included in other assets in the Consolidated Balance Sheets. One of the Company’s investments, with a book value of $2.6 million at December 31, 2024 is being accounted for using the cost method and, accordingly, is valued at cost less impairments, if any. The Company’s other investment is accounted for using the equity method. Accordingly, the Company records its share of the investee’s operating results each period, which are included in gains on investments, net in the Consolidated Statement of Operations. The Company recorded $0.8 million, $0.2 million and $0.3 million in gains from its non-marketable investments for the years ended December 31, 2024, 2023 and 2022, respectively. The Company uses the cumulative earnings approach to classify distributions received from equity method investments. During the years ended December 31, 2024, 2023 and 2022, no distributions were received from the funds.

Non-Marketable Investments

12 Months Ended

Dec. 31, 2024

Investments, Debt and Equity Securities [Abstract]

Note 9 – Non-Marketable Investments

At December 31, 2024 and 2023, the carrying value of the Company’s non-marketable investments, which were composed of interests in technology-related private equity funds and an interest in a standalone real-time feedback company (see Note 2 - Divestiture), was $3.2 million and $1.2 million, respectively, and are included in other assets in the Consolidated Balance Sheets.

One of the Company’s investments, with a book value of $2.6 million at December 31, 2024 is being accounted for using the cost method and, accordingly, is valued at cost less impairments, if any. The Company’s other investment is accounted for using the equity method. Accordingly, the Company records its share of the investee’s operating results each period, which are included in gains on investments, net in the Consolidated Statement of Operations. The Company recorded $0.8 million, $0.2 million and $0.3 million in gains from its non-marketable investments for the years ended December 31, 2024, 2023 and 2022, respectively.

The Company uses the cumulative earnings approach to classify distributions received from equity method investments. During the years ended December 31, 2024, 2023 and 2022, no distributions were received from the funds.